Davide Buonocore
Overview
Explore the profile of Davide Buonocore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
39
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parlati A, Nardi E, Basile C, Paolillo S, Marzano F, Chirico A, et al.
J Public Health Res
. 2024 Oct;
13(4):22799036241278817.
PMID: 39398345
Cardiovascular diseases (CVD) and mental health disorders (MHD) are respectively the first and second most prevalent diseases in high-income countries and the two most relevant causes of disability worldwide. The...
2.
Gargiulo P, Basile C, Galasso G, Bellino M, DElia D, Patti G, et al.
Eur J Prev Cardiol
. 2024 May;
31(15):1806-1816.
PMID: 38788773
Aims: No data are available on early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in patients with acute coronary syndrome (ACS) in the real world. This study investigates...
3.
Basile C, Parlati A, Paolillo S, Marzano F, Nardi E, Chirico A, et al.
Medicina (Kaunas)
. 2023 May;
59(5).
PMID: 37241180
: Depression is a common and severe comorbidity among individuals with heart failure (HF). Up to a third of all HF patients are depressed, and an even higher proportion have...
4.
Gargiulo P, Basile C, Cesaro A, Marzano F, Buonocore D, Asile G, et al.
Atherosclerosis
. 2023 Jan;
366:32-39.
PMID: 36696749
Background And Aims: Proprotein Convertase Subtilisin/Kexin type 9 inhibitors (PCSK9i) are recommended in patients at high and very-high cardiovascular (CV) risk, with documented atherosclerotic CV disease (ASCVD), and for very-high...
5.
Basile C, Paolillo S, Gargiulo P, Marzano F, Asile G, Parlati A, et al.
J Cardiovasc Med (Hagerstown)
. 2022 Dec;
24(1):44-51.
PMID: 36574300
Background: The impact of sacubitril-valsartan on heart failure (HF) patients with preserved ejection fractions (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the clinical advantages and safety...
6.
Gargiulo P, Marzano F, Salvatore M, Basile C, Buonocore D, Parlati A, et al.
ESC Heart Fail
. 2022 Nov;
10(2):753-761.
PMID: 36349485
Heart failure is a leading cause of morbidity and mortality, with relevant social and economic burden on global healthcare system. Although the development of novel diagnostic tools and the advance...
7.
Prastaro M, Nardi E, Paolillo S, Santoro C, Parlati A, Gargiulo P, et al.
J Clin Ultrasound
. 2022 Oct;
50(8):1110-1124.
PMID: 36218199
Cardiorenal syndrome is a clinical condition that impacts both the heart and the kidneys. One organ's chronic or acute impairment can lead to the other's chronic or acute dysregulation. The...